The CXCR4‐CXCL12 axis is linked to poor clinical outcomes in DLBCL,59 and a CXCR4 antagonist has already shown tumor suppressive effects on aggressive B‐cell lymphomas in vitro.60 Here, CXCR4 is linked to neoplasm.